Vanguard Capital Management’s Ovid Therapeutics OVID Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$19.5M Buy
7,828,361
+68,247
+0.9% +$179K ﹤0.01% 2411
2026
Q2
$20.9M Buy
7,760,114
+2,501,868
+48% +$6.46M ﹤0.01% 2424
2026
Q1
$11.7M Buy
+5,258,246
New +$9.4M ﹤0.01% 2647

Other funds holding OVID

Vanguard Capital Management's OVID Position: Q3 2026 in Review

Vanguard Capital Management increased its Ovid Therapeutics (OVID) stake by 0.88% in Q3 2026, buying an estimated $179K and bringing the position to 7,828,361 shares worth $19.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2411.

Vanguard Capital Management first reported a position in OVID in Q1 2026 and has held it in 3 quarters since. The position peaked at $20.9M in Q2 2026. 129 funds tracked by Wall St. Rank hold OVID as of Q3 2026.

  • Vanguard Capital Management held 7,828,361 shares of Ovid Therapeutics worth $19.5M as of Q3 2026.
  • Vanguard Capital Management bought 68,247 Ovid Therapeutics shares in Q3 2026, an estimated $179K.
  • Ovid Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2411 holding.
  • Vanguard Capital Management first reported a position in Ovid Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Ovid Therapeutics position peaked at $20.9M in Q2 2026.
  • 129 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.